Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy
Cell Biology International · 2025
DOI: 10.1002/cbin.70082 ↗At a glance
Übersichtsarbeit in Cell Biology International, 2025. Written by Iqra Khurram and 7 co-authors. Institution: Precision Genomics Research Lab, Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan. Major MEDLINE topics: Cystic Fibrosis, Gene Editing, CRISPR-Cas Systems, Genetic Therapy. Cited 1 times so far (Crossref); 122 references.
Abstract (original language)
Cystic fibrosis (CF) is an inherited, autosomal recessive disorder that is caused by mutations in the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). CFTR maintains the balance between water and salts by transporting chloride ions along various epithelial surfaces. CFTR impairment affects the function of several organs, including the lungs. Newborn screening, prenatal diagnosis, and pharmacological interventions have altered the prevalence and incidence of cystic fibrosis. Although CFTR modulators are a promising treatment option, their ability to target and correct only one mutation at a time restricts their therapeutic potential. The development of genome editing technologies such as Clustered Regularly Interspaced Short Palindromic Repeats‐Cas(CRISPR‐Cas9) has the potential to correct genetic mutations, including those associated with CF, thereby offering a permanent treatment by fixing the root cause of CF. This article summarizes cystic fibrosis development, prognosis, and diagnosis, as well as possibilities for correcting various types of CFTR gene mutations. The review focuses on the potential of gene editing technologies to repair CFTR mutations and their applications in the advancement of CF treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Precision Genomics Research Lab, Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan.
- Department of Human Genetics & Molecular Biology, University of Health Sciences, Lahore, Punjab, Pakistan.
- Allama Iqbal Medical College/Jinnah Hospital, Lahore, Punjab, Pakistan.
- Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Punjab, Pakistan.
ORCID profiles: Iqra Khurram, Mahmood S Choudhery, Muhammad Usman Ghani, Taqdees Arif, Aiza Naeem, Ruhma Mahmood, Ahmad Niaz, Muhammad Umer Khan
Cite
APA
Khurram, I., Choudhery, M. S., Ghani, M. U., Arif, T., Naeem, A., Mahmood, R., Niaz, A., & Khan, M. U. (2025). Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy. Cell Biology International. https://doi.org/10.1002/cbin.70082
Vancouver
Khurram I, Choudhery MS, Ghani MU, Arif T, Naeem A, Mahmood R, et al. Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy. Cell Biology International. 2025. doi:10.1002/cbin.70082
BibTeX
@article{Khurram2025,
author = {Khurram, Iqra and Choudhery, Mahmood S and Ghani, Muhammad Usman and Arif, Taqdees and Naeem, Aiza and Mahmood, Ruhma and Niaz, Ahmad and Khan, Muhammad Umer},
title = {Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.70082}
}
EUVIMED